Imatinib is an effective therapy for chronic myeloid leukemia (CML), a myeloproliferative disorder characterized by the expression of the recombinant oncoprotein Bcr-Abl. In this investigation, we studied an imatinib-resistant cell line (K562-r) generated from the K562 cell line in which none of the previously described mechanisms of resistance had been detected. A threefold increase in the expression of the heatshock protein 70 (Hsp70) was detected in these cells. This increase was not associated to heat-shock transcription factor-1 (HSF-1) overexpression or activation. RNA silencing of Hsp70 decreased dramatically its expression (90%), and was accompanied by a 34% reduction in cell viability. Overexpression of Hsp70 in the imatinib-sensitive K562 line induced resistance to imatinib as detected by a large reduction in cell death in the presence of 1 lM of imatinib. Hsp70 level was also increased in blast cells of CML patients resistant to imatinib, whereas the level remained low in responding patients. Taken together, the results demonstrate that overexpression of Hsp70 can lead to both in vitro and in vivo resistance to imatinib in CML cells. Moreover, the overexpression of Hsp70 detected in imatinibresistant CML patients supports this mechanism and identifies potentially a marker and a therapeutic target of CML evolution.
Introduction
Chronic myeloid leukemia (CML) is characterized by the expression of the recombinant Bcr-Abl oncoprotein, which is the result of a t(9;22)(q11;q34) reciprocal translocation that generates a shortened chromosome 22 or Philadelphia (Ph) chromosome. Bcr-Abl is the main target of the tyrosine kinase inhibitor imatinib mesylate (Gleevec or Glivec, previously STI571), which also inhibits c-Kit (the receptor for SCF), the PDGF receptor, Abl and the Abl-related gene. 1, 2 Imatinib is a 2-phenylaminopyrimidine that binds to the inactive form of the Bcr-Abl kinase, blocking the change in conformation required for activation, thus preventing the binding of ATP. 3, 4 The resulting inhibition of the kinase activity leads to apoptosis of leukemic cells sparing normal hematopoiesis. 5, 6 Imatinib is now used as the front-line therapy of CML disease. However, in vivo some patients do not respond to imatinib treatment (primary resistance), or relapse after an initial response (acquired resistance). 7, 8 The frequency of resistance to imatinib increases in accelerated phase (40%) and even further in blast crisis (78%). 9, 10 Overcoming resistance to imatinib remains a challenge for successful treatment of CML, particularly in the advanced phases. 4, 11 Among the different mechanisms identified both in vitro and in vivo, resistance is mainly mediated by mutations within the kinase domain of Bcr-Abl, amplification of the BCR-ABL genomic locus or abnormalities downstream of Bcr-Abl such as Src family kinase hyper-expression. 12 Amplification of Bcr-Abl kinase has been reported in some CML patients leading to imatinib resistance. 13, 14 Bcr-Abl-independent resistance mechanisms include drug sequestration or efflux, mediated, respectively, by the alpha-1-acid glycoprotein or the multidrug resistance 1 gene product. [15] [16] [17] We have previously generated an imatinib-resistant K562-r cell line, by growing the imatinib-sensitive parental K562 cells (K562-s) in increasing concentrations of imatinib. 18 None of the conventional mechanisms of imatinib resistance was identified in that cell line. In the current study, we undertook a proteomic analysis of K562-s and K562-r cells and detected differential expression of the heat-shock protein 70, Hsp70. For instance, Hsp are molecular chaperones that bind to unfolded or misfolded proteins to ensure their proper folding and prevent intracellular protein aggregation, but other roles have also been highlighted by detection of interacting proteins involved in signaling pathways. 19, 20 Interestingly, Hsp70 expression is induced by cellular stress and is increased in acute leukemia mediating partially the antiapoptotic effect of Bcr-Abl. 21 Hsp70 is involved in antiapoptotic pathways by inhibition of apoptotic signals. [22] [23] [24] An indirect antiapoptotic role of Hsp70 is also reported by its interaction with the co-chaperone CHIP, also called BAG-1, which leads to the proteasomal degradation of proapoptotic proteins. 25, 26 All these antiapoptotic roles suggest that Hsp70 may be involved in resistance to imatinib, similarly to its participation in other forms of drug resistance. 21, 27, 28 In the present study, we confirm that the K562-r cells resistant to imatinib are also resistant to nilotinib, the novel tyrosine kinase inhibitor (AMN107) that was initially developed as a potent Bcr-Abl inhibitor based on the molecular structure of imatinib. We detect by Western blotting that Hsp70 is overexpressed in K562-r cells, as compared to their imatinib-sensitive counterparts. Inhibition of Hsp70 expression by short interfering RNA (siRNA) led to a rapid decrease in Hsp70 level, which was followed by a reduction of cell viability in the presence of imatinib. Moreover, ectopic overexpression of Hsp70 in K562-s cells allowed them to survive in the presence of 1 mM imatinib, in contrast to the rapid cell death incurred by the parental K562-s cells in the presence of the inhibitor. Finally, detection of Hsp70 protein level in blast cells of CML patients resistant to imatinib clearly shows an overexpression of Hsp70, whereas it remained weak in imatinibsensitive patients.
Materials and methods

Reagents
Roswell Park Memorial Institute RPMI 1640 medium, fetal calf serum (FCS), phosphate-buffered saline (PBS), trypan blue and antibiotics were from Invitrogen (Cergy Pontoise, France). Imatinib and nilotinib were kindly provided by Novartis Pharma (Basle, Switzerland). MTS was purchased from Promega (Charbonnières, France). Polyacrylamide (30/0.8), molecular weights markers and polyvinylidene fluoride (PVDF) membrane were from BioRad (Marnes La Coquette, France). The siRNA used in this study were 23-bp oligonucleotides from Qiagen (Courtaboeuf, France). The pmax-GFP plasmid was provided by Amaxa (Amaxa, Cologne, Germany), pDs-Red2 was from Clontech (0zyme, Saint Quentin Fallavier, France) and the pcDNA3-Hsp70-HA was kindly provided by C Garrido (Faculty of Medicine, Dijon, France). All reagents for two-dimensional (2D) electrophoresis were purchased from Amersham (GE HealthCare, Orsay, France). Cell culture K562 cells (2 Â 10 5 cells/ml) were grown at 371C and 5% CO 2 in RPMI 1640 medium supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin, here referred to as 'RF-10'. For the K562-r imatinib-resistant cell line, the RF-10 media were further supplemented with 1 mM imatinib, as described previously. 18 
Cell proliferation assay
This was performed using MTS tetrazolium (Cell Titer96 Aqueous, Promega, Madison, WI, USA) that measures cell proliferation by the number of viable cells. Washed cells in RPMI 1640 medium were plated (10 4 cells) in quadruplicate into microtiter-plate wells plus various doses of imatinib (STI571) or nilotinib (AMN 107). Measure of viability was performed on a 4-day kinetic and each day 20 ml of MTS were added to the wells. After 2 h incubation at 371C, the plates were read in a microplate autoreader (Dynex Technologies, Billingshurst, UK) at the wavelength of 490 nm. The results are expressed as the mean optical density (OD) of the four-well set for each inhibitor dose. All the experiments were repeated at least three times.
Primary cells from CML patients
All patients in this study were in blast crisis with at least 60% of blast cells in the peripheral blood. Written informed consent to the use of their cells in the following study was obtained for all cases, according to the requirements of the local research ethics committee. None of the patients carried a mutated Bcr-Abl, as shown by sequencing of the tyrosine kinase and SH 2 domains. 29 Blast cells were isolated by density-gradient separation from peripheral blood or bone marrow specimens from CML patients. After isolation, blast cells were cryopreserved at 10 7 /ml in liquid nitrogen. To prepare protein samples, the cells were rapidly thawed, washed three times in PBS and 5 Â 10 6 cells were solubilized in lysis buffer (NaH 2 PO 4 10 mM (pH 7.4), NaCl 150 mM, ethylenediaminetetraacetic acid (EDTA) 5 mM, Triton X-100 1%) supplemented with 2 mM Na 3 VO 4 , 2 mM phenylmethylsulfonyl fluoride (PMSF), 10 mM NaF and protease inhibitors (10 mg/ml aprotinin, 10 mg/ml leupeptin and 10 mg/ml pepstatin).
Gel electrophoresis
2D electrophoresis and mass spectrometry were performed as described. 30 ,31 K562 cells ( 10 7 ) were washed, solubilized in 2D buffer (9 M urea, 4% (w/v) CHAPS, 65 mM dithiothreitol (DTT), 0.5% immobilized pH gradient (IPG) buffer (pH 3-10) non linear (NL), 40 mM Tris (pH 7.4)). Protein concentration was quantified using the 2D Quant kit (GE HealthCare, Orsay, France). Immobilized pH gradient (IPG) strips (pH 3-10 NL) were rehydrated in the presence of the sample (500 mg, 12 h at 30 V at 201C) and focusing was performed on an Ettan IPGphor as follows : 1 h at 200 V, 1 h at 500 V, 1 h at 1000 and 8000 V for a total of 16 000 kV-h. The strips were then incubated in 50 mM Tris (pH 7), 6 M urea, 2% sodium dodecyl sulfate (SDS), 30% glycerol supplemented with 65 mM DTT for 15 min under continuous shaking, followed by a further 15 min incubation in the same buffer supplemented with 2.5% (w/v) iodoacetamide. The second dimension was a standard SDS-polyacrylamide gel electrophoresis (SDS-PAGE) protocol. After Coomassie blue staining, the gels were scanned and differential protein expression profiles were compared using ImageMaster 2D Platinum software (GE HealthCare, Orsay, France). Spots of interest were excised from the gel, followed by destaining, reduction, alkylation and overnight hydrolysis at 371C with trypsin. Liquid chromatography coupled to electrospray tandem mass spectrometry was performed in the department of proteomic of Bordeaux University. SWISS-PROT and TrEMBL database searches of tryptic peptide masses were carried out using the SEQUEST search tool (Matrix Science, London, UK).
Inhibition of Hsp70 expression by RNA silencing
In order to inhibit Hsp70 protein expression, the K562-s and K562-r cultures were first stabilized at a 495% viability. Two million cells were washed three times in cold PBS, resuspended in 100 ml nucleofection solution (Amaxa kit V) and mixed with no siRNA or 5 mg of Alexa 488-labeled siRNA corresponding to a negative control siRNA (irrelevant sequence) or Hsp70 siRNA (specific to nucleotides 464-484). Transfection was performed according to the manufacturer's instructions using the protocol T03 (Amaxa). Cells were seeded at 2 Â 10 5 /ml in RF-10 for 4 h, after which they were grown with or without 1 mM imatinib. Aliquots of the culture were harvested daily for protein expression analysis and measurement of cell viability by flow cytometry and by triplicate trypan blue exclusion counts. Experiments were performed no longer than 4 days and were 
Overexpression of Hsp70 expression
K562-s cells in the exponential growing phase (2 Â 10 6 /ml) were transfected with either no DNA (control), 2.5 mg pmax-GFP (control for transfection efficiency) or 0.5 mg pmax-GFP plus 5 mg pcDNA3-Hsp70-HA, according to the manufacturer's protocol, and seeded at 2 Â 10 5 /ml. After 4 h, transfected cells were separated into two aliquots, and grown with or without 1 mM imatinib for 2 days. Aliquots were taken daily for protein expression analysis and for measurement of proliferation and viability by triplicate trypan blue exclusion counts and flow cytometry using propidium iodine staining. Experiments were repeated five times and results are presented as the mean7s.d.% of viable cells. Statistical analysis was carried out by Student's t-test. As transfection ratio was between 50 and 60%, we underestimate the induced resistance to imatinib generated by Hsp70 overexpression. To analyze the resistance to imatinib only in transfected over-expressing Hsp70, cotransfection were performed as above with PMMD-Ds-Red2 (1 mg) and pcDNA3-Hsp70 (5 mg). After transfection, cells were grown as above and the ratio of transfected cells was estimated by detection of the Ds-Red2 fluorescence by flow cytometry. Albeit only 20% of cells were Ds-Red positive, flow cytometry detection using Annexin V-FITC allowed us to measure apoptosis in response to 1 mM imatinib in 2 days course.
Flow cytometry
Briefly, cells (5 Â 10 4 cells in 100 ml of RF-10 media) were incubated for 10 min in the presence of 0.25 mg of propidium iodine. The sample was then diluted five times in PBS and analyzed on an Epics XL (Beckmann Coulter, Villepinte, France). Fluorescent siRNA or green fluorescent protein (GFP) and propidium iodine (0.5 mg/ml) were detected on fluorescent channels 1 and 2, respectively. The percentages of transfected, living and dead cells were calculated from acquiring a total of 10 000 events. Results are indicated as follows: percent of transfected cells (B1 and B2) and untransfected (B3 and B4), viable cells (B1and B3) and dead cells (B2 and B4) was quantified by using Coulter software. To measure apoptotic cells, analysis was performed on Ds-Red2-positive cells and apoptosis induced by imatinib was detected by the measurement of annexin-V-FITC-labeled positive cells. Experiments were repeated three times.
SDS-PAGE and Western blotting
Two million cells were washed three times in cold PBS, and the cell pellet was solubilized in 100 ml of lysis buffer or sample buffer (4 mM Tris (pH 6.8), 4% SDS, 20% glycerol) and boiled at 951C for 10 min as described. 32 Protein concentration was measured by the BCA Protein Assay (Pierce, Rockford, IL, USA) and the lysates were stored at -801C. Proteins were resolved by SDS-PAGE and transferred onto PVDF membrane. After 1 h saturation in 10% bovine serum albumin and overnight incubation with the primary antibody, binding of the horseradish peroxidase-coupled secondary antibodies were detected by chemiluminescence. The quantification of Hsp70 was performed by using the ImageJ software (www.rsb.info.nih. gov/ij), and antibodies against Crkl or actin were used as loading controls.
Results
Hsp70 is overexpressed in the imatinib-resistant K562
Proliferation assay was performed on the imatinib-sensitive (K562-s) and -resistant (K562-r) cell lines to measure the response to imatinib and nilotinib, the next generation of BcrAbl inhibitor derived from imatinib. Both imatinib and nilotinib inhibited proliferation of K562-s at concentration as low as 0.1 mM and 0.5 nM respectively, whereas they were unable to inhibit proliferation of K562-r at 10 mM imatinib and 100 nM nilotinib (Figure 1a) albeit the kinase activity of Bcr-Abl was fully blocked (not shown). This result suggests that imatinib resistance is independent of Bcr-Abl kinase activity. In an attempt to identify the difference between K562-s and K562-r, a differential proteomic display has been performed. Among the proteins differentially expressed between K562-s and K562-r and identified by mass spectrometry, Hsp70 is one of the overexpressed proteins in K562-r (Figure 1b ) (M Pocaly et al., unpublished results). In light of the reported role of Hsp70 in inhibiting apoptotic mechanisms in acute leukemia, we focus on and investigate Hsp70 role in imatinib resistance. 21 To confirm the results obtained by 2D gel electrophoresis, the level of Hsp70 expression was compared by Western blotting on K562-s and K562-r. The result illustrated in Figure 1c shows that Hsp70 is increased in the K562-r cells. Densitometry analysis performed on five different samples showed that Hsp70 expression was increased threefold in K562-r as compared to K562-s. The level of overexpression was confirmed by immunoblotting with two different anti-Hsp70 antibodies (not shown).
As expression of Hsp70 is induced by HSF-1-mediated activation of the transcription of the HSP70 gene, we detect the level of expression and the phosphorylation status of HSF-1 in K562-s and K562-r. HSF-1 was detected as a double band in K562-s and K562-r with a similar level of expression (Figure 1d ). The detection of HSF-1 in the soluble and in the insoluble fractions (supernatant and pellet) of NP-40 lysates or in SDS lysates of K562-s and K562-r did not show any difference, suggesting that neither the level, the subcellular location nor the phosphorylation status of HSF-1 is different (result not shown). To determine if HSF-1 could be activated and induced Hsp70 expression, we used geldanamycin, an inhibitor of Hsp90, which induced the release of HSF-1 from Hsp90 and allowed it to prime the transcription of the Hsp70 gene. Incubation with geldanamycin (1 mM for 24 h) did not change significantly the whole amount of HSF-1 albeit an increase of the expression of Hsp70 in K562-s, but no change in K562-r, suggesting that Hsp70 is already expressed at maximum. The similar phosphorylation pattern of HSF-1 between K562-s and K562-r lead us to further investigate if more HSF-1 phosphorylation could be induced in our model cell line. In attempt to answer this, we compare the level of HSF-1 phosphorylation in K562-s and K562-r cells in response to heat-shock (451C 1 h) or upon pervanadate incubation (500 mM 1 h). Both treatments induce the phosphorylation of HSF-1 to a similar level in K562-s and K562-r, as detected by the appearance of a third higher molecular band, but this was not accompanied by an increase in the level of expression of the Hsp70 protein owing to the shorter time point used in our experiment.
to grow in the continuous presence of 1 mM imatinib. To test this hypothesis, an siRNA specific for Hsp70 was designed and used to inhibit Hsp70 expression in K562-r. These cells were transfected with either the Hsp70 or the control siRNA. Twelve hours after transfection, more than 90% of cells contained the siRNA (Figure 2a) . A small but significant difference in the proportion of dead cells (propidium iodinelabeled cells, B2 þ B4, 16.5 versus 9.1%) was measured between the Hsp70 siRNA and the control transfected cells, showing that inhibition of 30% of Hsp70 decreased the viability of K562-r by 10% in the presence of imatinib. In comparison to the controls (no siRNA or control siRNA), the siRNA targeting Hsp70 led to a rapid decrease of Hsp70 expression, which fell less than 10% at day 4 ( Figure 2b ). Viability was reduced to 85% in K562-r transfected with Hsp70 siRNA at day 1 and reached 6676% at day 4 (n ¼ 5, Po0.05) in comparison to controls (Figure 2c ). These results show that inhibition of Hsp70 expression in K562-r partially restores the sensitivity to imatinib, confirming the role of Hsp70 in the in vitro resistance to imatinib of this cell line. Moreover, viability of Hsp70 siRNAtransfected K562-r is not modified in the absence of imatinib (not shown). In parallel, the inhibition of Hsp70 by siRNA in K562-s does not affect viability and does not change significantly the sensitivity to imatinib (not shown).
Overexpression of Hsp70 in K562-s induces resistance to imatinib
Based on the finding that Hsp70 was over-expressed in K562-r, we next induced increased expression of Hsp70 in K562-s to potentially induce resistance to imatinib. For this purpose, K562-s cells were co-transfected with a pcDNA3 coding for a HA-tagged Hsp70 and with pmax-GFP to monitor the transfection efficiency. The proportion of GFP-expressing cells was always in the range of 50-60% 12 h after transfection and remained unchanged in the course of the experiment (not shown). Concomitantly, a twofold increase in Hsp70 expression in comparison to the controls (control and K562-s transfected with pmax-GFP) was detected by Western blot at day 2 ( Figure 3a , the top band corresponds to the Ha-tagged Hsp70 and the bottom band to the endogenous Hsp70). The inhibition of Bcr-Abl tyrosine kinase activity by incubation with 1 mM imatinib triggered a large apoptosis in K562-s in 3 days (over 70% of dead cells) impeding the analysis of protein in the resting viable cell population. This led us to measure the expression of Hsp70 and cell viability at 48 h after the addition of imatinib. Whereas control or transfected cells with 5 mg of pmax-GFP showed an increase in cell death (5274%), Hsp70-transfected cells experienced a significantly lower rate of viability loss (2674%) upon exposure to imatinib (Figure 3b) . The difference in mortality between controls and Hsp70-transfected cells treated with 1 mM imatinib correlated with the overexpression of Hsp70, suggesting that the sensitivity of K562-s to the killing effects of imatinib was attenuated by the hyperexpression of Hsp70. Indeed, the partial transfection between 50 and 60% suggested we underestimate the induced resistance to imatinib generated by Hsp70 overexpression. In an attempt to confirm that only overexpressing Hsp70 cells are resistant to imatinib, co-transfection experiments were performed with 1 mg of Ds-Red and 5 mg of pcDNA3-Hsp70. Ds-Red-positive 
Detection of Hsp70 in cells from imatinib-treated patients
Overexpression of Hsp70 being correlated with the resistance to imatinib in our model cell line, we investigated the expression of Hsp70 in blast cells of imatinib-responding and imatinibresistant CML patients. None of these patients exhibited Bcr-Abl kinase mutations or gene amplification, the two most common mechanisms of resistance. ) in the exponential growing phase (day 0) were transfected with no siRNA (control), 5 mg Alexa-488-labeled control siRNA (siRNA Neg) or 5 mg Alexa-488-labeled siRNA Hsp70 (siRNA Hsp70). After recovery (4 h after transfection), 1 mM of imatinib was added in the culture medium. Every day (d1-d4) an aliquot was taken for counting cell viability using trypan blue exclusion, propidium iodine labeling and detection of Hsp70 expression level by Western blotting. (a) Flow cytometry data illustrate the dual parameters dot-plot analysis of Alexa 488 (Alexa 488) and propidium iodine (PI). Fifty thousand cells were incubated with propidium iodine to measure transfection efficiency (Alexa 488) and dead cells (PI labeling) by flow cytometry. Results were from the analysis of K562-r on day 0 (d0) before transfection and on day 1 (d1) for K562-r transfected with siRNA Neg or Hsp70 siRNA. Results shown are representative of five experiments. (b) Western blotting was performed on K562-r protein samples (d0: K562-r; d1-d4: siRNA Neg or siRNA Hsp70). Membranes were probed for Hsp70 and actin for loading control. Arrows on the right show the target proteins. Densitometry analysis was performed on five different Western blotting as described in Materials and methods. (c) Cell viability was measured by counting viable and dead cells using the trypan blue exclusion assay. Results shown are the mean7s.d. of five independent experiments (n ¼ 5) and viability of K562-r at d0 was 95%. Statistics were performed by Student's t-test by dual parameters analysis, the asterik indicates Po0.05, comparing the samples siRNA Hsp70 versus siRNA Neg.
Heat Figure 4a , Hsp70 is weakly expressed in cells of CML patients in blast crisis responding to imatinib. In contrast, in eight imatinib-resistant patients in blast crisis, Hsp70 is over-expressed with a two to 6.5-fold increase in comparison to the imatinib-responding cell patients. Although the percent of blast cells may vary between samples, it was above 60%
showing that the level of Hsp70 detected is correlated to the resistance to imatinib.
We also detect the level of Hsp70 in cells of CML patients in blast crisis during the course of imatinib treatment and who developed primary or acquired (secondary) resistance to imatinib. Indeed, retrospectively these patients were either resistant in first instance (primary resistance) or were responding to imatinib at the beginning of treatment, but relapse after few weeks (acquired resistance). A low level of Hsp70 was detected Heat-shock protein 70 and imatinib resistance M Pocaly et al in blast cells of three patients responding to imatinib (Figure 4b ) and it detected a hematological response in the following weeks of imatinib treatment. However, the level of Hsp70 in the blast cells of the same patients at the relapse time was dramatically increased (Figure 4b) . A high level of Hsp70 was also detected in blast cells of primary imatinib-resistant patients (Figure 4c ) emphasizing the role of Hsp70 in imatinib resistance.
Discussion
Imatinib is the treatment in front-line of CML de novo, which induced complete hematologic remissions in most CML patients in chronic phase. 33 Novel tyrosine kinase inhibitors like nilotinib (AMN107) or dasatinib (BMS-354825) will replace imatinib in the treatment of resistant CML patients. Even if resistance to imatinib occurs in a small number of chronic phase patients, the frequency increases in the accelerated phase or blast crisis. 9, 34 In vivo, resistance to imatinib is mainly the result of point mutations within the kinase domain of Bcr-Abl. 29, 35, 36 However, there is still imatinib resistance for which mechanisms have still to be identified.
In this study, we have used an imatinib-resistant K562 cell line, K562-r, derived from the sensitive parental K562, K562-s, for which all of the previously described mechanisms of resistance had been detected. 18 The lack of inhibition of imatinib or nilotinib on K562-r even at high concentration, whereas Bcr-Abl tyrosine kinase activity was shut down, rule out a possible role of Bcr-Abl overexpression in the resistance mechanism of K562-r. Furthermore, not any increase of the Src kinase Lyn or Hck was detected in the K562-r. Results from a proteomic study point out the different level of expression of several Hsp between K562-s and K562-r (M Pocaly et al., unpublished result). Among them, we focused on the Hsp70 and we confirmed by Western blot the overexpression of Hsp70 detected by 2D gel analysis as a threefold increase. This overexpression of Hsp70 has to be clearly separated from the Hsp70 induction by Bcr-Abl as both K562-s and K562-r expressed a similar level of Bcr-Abl. 21, 37 To determine if the overexpression of Hsp70 is related to an increase of its messenger, we measured by quantitative polymerase chain reaction (PCR) the mRNA of Hsp70 in K562-s and K562-r and detected a threefold increase. Hsp70-inducible expression is under the control of the HSF-1 and through a GATA response element in Bcr-Abl-expressing cells. 28 HSF-1 is activated and localized to the nucleus in response to stress by homotrimerization and phosphorylation. 38, 39 The detection of the level of expression and phosphorylation of HSF-1 in our in vitro model (in K562-s and K562-r) and in blast cells of CML patients did not show significant difference (data not shown). However, the lack of difference of HSF-1 expression, subcellular location and phosphorylation between K562-s and K562-r, even if K562-r overexpressed Hsp70, may be explained by several mechanisms such as the sequestration of HSF-1 by Hsp70 or Hsp90, 38, 40 although Hsp70 overexpression may be mediated by a HSF-1-independent mechanism. Indeed, geldanamycin treatment was unable to increase the level of Hsp70 in K562-r, suggesting that the level of expression was already maximal. According to the mechanism reported by Ray et al., 28 the upregulation of Hsp70 through a GATA response element activation, Hsp70 overexpression may be mediated by a related mechanism in K562-r, although the sequence of the promoter of the Hsp70 gene was identical (not shown). Another mechanism may be the 'bookmarking' of the Hsp70 promoter by HSF-2 and may be taken into account to explain the increase of expression of Hsp70 in pathological condition. 41 HSF-2 also interacts with HSF-1 mediating the transcriptional enhancement of Hsp70 in the K562 cell line. 42, 43 Such a mechanism, if dysregulated, could explain the overexpression of Hsp70 in K562-r.
To investigate the function of Hsp70, its expression was inhibited in K562-r by siRNA and sensitivity to imatinib was tested. The inhibition of Hsp70 expression in K562-r decreases the resistance to imatinib leading to a 34% reduction of cell viability in the presence of imatinib. This effect is impaired in the absence of imatinib. However, the limit of our study was the short time course no longer than 4 days. In an attempt to confirm that overexpression of Hsp70 induce resistance to imatinib, ectopic expression of Hsp70 was induced in the K562-s cells. The ectopic expression induced a twofold increase in Hsp70 protein level and allowed to grow them for 48 h in the presence of 1 mM imatinib with a better viability than control K562-s confirming that overexpression of Hsp70 is involved in cell survival, despite the exposure to 1 mM imatinib. This is in agreement with the study of Ray et al. 28 showing that drug resistance is correlated to the upregulation of Hsp70 leading to antiapoptotic pathways. Indeed, detection of imatinib-induced apoptosis by Annexin-V binding specifically in cells overexpressing Hsp 70 (Ds-Red positive cells, Figure 3c) show a resistance to imatinib in contrast to the control cells which have a strong increase in cell death after 2 day (5 versus 47% of mortality) confirming that Hsp 70 overexpression is involved in resistance.
We have studied the level of Hsp70 in blast cells of CML patients. Hsp 70 is weakly expressed in blast cells of imatinibresponding CML patients, whereas it detected a two to six-fold increase in blast cells of imatinib-resistant patients. Additional proof of Hsp70-mediated resistance to imatinib came from the level of Hsp70 detected at the beginning of imatinib treatment and few weeks later. For patients who were first responding to imatinib and then relapse, a large increase in the level of Hsp70 was detected at relapse time, whereas for primary imatinibresistant patients, a high level of Hsp70 was detected both at the beginning and later. Guo et al. 21 have reported that Bcr-Abl induces Hsp70 expression enhancing antiapoptotic signaling leading to drug resistance. This contribution of Bcr-Abl may explain the expression of Hsp70 in the K562-s cells but not the overexpression detected in K562-r or in blast cells of imatinibresistant patients as they had no overexpression of Bcr-Abl. Indeed, we were unable to detect an increase of expression and phosphorylation of STAT5 in K562-r, although they reported that Hsp70 overexpression has both a STAT5-dependent and -independent component. 21 The multiple mechanisms of Hsp70-mediated antiapoptotic pathways are well described and could explain the resistance to drugs as those recently described in carcinoma. 44, 45 However, a threefold increase in Hsp70 expression may not be sufficient to prevent imatinibinduced apoptosis of leukemic cells, suggesting that in our K562-r cell line Hsp70 may play an indirect role. To identify the exact antiapoptotic signaling involved in the resistance to imatinib, we might study which pathways are involved. For instance, the detection of the Hsp70 binding proteins will allow to identify the partners and the underlying signaling involved.
Conclusion
In summary, this study shows that weak Hsp70 overexpression is enough to induce imatinib resistance in vitro. It will be noteworthy to study the level of Hsp70 in a larger panel of CML patients in accelerated phase and blast crisis to validate if Heat-shock protein 70 and imatinib resistanceHsp70 is a good prognostic marker of resistance in this disease. Moreover, the study of the molecular mechanisms implicated in the overexpression of Hsp70 during the late phase of the CML disease may provide a solution to bypass drug resistance and this is under investigation.
